From Ideas to Impact: Emerging Health Technologies in Action

1 – 2 Jun 2026 | Brussels, Belgium

Project cooperationUpdated on 1 June 2026

Dbamy o Zdrowie i biznes

Prezes i dyrektor projektu at MŚP

Warszawa, Poland

About

Partner Collaboration – Innovative Energy Solutions

We are a manufacturer of advanced energy technologies, specializing in mobile energy sources and solutions for crisis situations. Our products are based on R&D&I (Research, Development, and Innovation), tested prototypes, and extensive experience in the Deep Tech industry .

Stage

  • Planning

Topic

  • IHI Topic 1: IHI European healthcare incubator network
  • IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
  • HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
  • HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
  • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
  • HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
  • HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines

Type

  • Consortium looking for partners

Organisation

MŚP

Company (SME)

Warszawa, Poland

Similar opportunities

  • Project cooperation

    Digital Health & AI/ML SME | Real-World Data, Interoperability & Clinical AI Expertise Seeking CARMEN2026 Looking for a consortium to join with Widening Option

    • IHI Topic 1: IHI European healthcare incubator network
    • Partner offering expertise and is looking for a consortium
    • IHI Topic 3: Decode the immuno-science of age-related mediated diseases
    • HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
    • HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
    • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
    • HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
    • HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
    • IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
    • HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
    • HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
    • HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
    • HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
    • HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
    • HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
    • HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
    • HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

    Elifnaz Unay Kılıç

    EU Technology & Funds Manager at TİGA

    Ankara, Türkiye

  • Project cooperation

    PanGI Landmark Graph™ – Whole-Tract Capsule Intelligence

    • IHI Topic 1: IHI European healthcare incubator network
    • Partner offering expertise and is looking for a consortium
    • IHI Topic 3: Decode the immuno-science of age-related mediated diseases
    • HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
    • HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
    • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
    • HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
    • HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
    • IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
    • HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
    • HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
    • HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
    • HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
    • HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
    • HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
    • HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
    • HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

    Miadreza Shafiekhah

    Head of Research and Innovation at Nowocert

    Dublin, Ireland

  • Project cooperation

    MaternAI LiveCare™ – Continuous Lifestyle and Maternal Health Intelligence

    • IHI Topic 1: IHI European healthcare incubator network
    • Partner offering expertise and is looking for a consortium
    • IHI Topic 3: Decode the immuno-science of age-related mediated diseases
    • HORIZON-MISS-2026-02-CANCER-04: Earlier and more precise palliative care (RIA)
    • HORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research (RIA)
    • HORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of older cancer patients (RIA)
    • HORIZON-MISS-2026-02-CANCER-02: Microbiome for early cancer prediction before the onset of disease (RIA)
    • HORIZON_MISS-2027-02-CANCER-01 Leveraging functional genomics to reveal novel targets for cancer treatment
    • IHI Topic 2: An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
    • HORIZON-MISS-2026-02-CANCER-06: Development of a research capacity building programme on cancer with and for Ukraine (RIA)
    • HORIZON_MISS-2027-02-CANCER-02 Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers
    • HORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimise immunotherapeutic interventions for patients with refractory cancers (RIA)
    • HORIZON-MISS-2026-02-CANCER-05: Boosting mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) (IA)
    • HORIZON_MISS-2027-02-CANCER-06 Support a Young Cancer Survivor Quality of Life (QoL) research programme by cancer charities and funding agencies
    • HORIZON_MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
    • HORIZON_MISS-2027-02-CANCER-04 Improving equitable health outcomes and added value for and with cancer patients through health-economics research, health systems research and outcomes research
    • HORIZON_MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes

    Miadreza Shafiekhah

    Head of Research and Innovation at Nowocert

    Dublin, Ireland